News Formal

Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies

  • 📰 CNBC
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 72%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

Heavy debt, faltering in 2018, and cracks in the deal: Bristol-Myers Squibb's $74 billion acquisition of Celgene combines 2 troubled companies.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

That's like merging Deutsche Bank and Commerzbank. Guess 1-(-1) = 2

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 12. in İD

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Bristol-Myers takes $74 bln bet against the marketThere are good reasons to buy rival oncology giant Celgene. But cost cuts don’t cover the 54 pct premium and the target’s owners get the financial benefit. Bristol is hoping for luck in the courts and multiple regulatory approvals that Celgene’s shareholders were skeptical of.
Sumber: Breakingviews - 🏆 470. / 51 Baca lebih lajut »